| 1 |
Zhang J, Fu S, Liu D, Wang Y, Tan Y. Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2023;35:353-8. [PMID: 36719824 DOI: 10.1097/MEG.0000000000002517] [Reference Citation Analysis]
|
| 2 |
Deza Z, Caimi GR, Noelia M, Coli L, Ridruejo E, Alvarez L. Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway. Mol Carcinog 2023;62:398-407. [PMID: 36575946 DOI: 10.1002/mc.23494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Cho Y, Kim BH, Park JW. Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma. Clin Mol Hepatol 2023;29:S220-7. [PMID: 36353768 DOI: 10.3350/cmh.2022.0360] [Reference Citation Analysis]
|
| 4 |
Bitto N, Ghigliazza G, Lavorato S, Caputo C, La Mura V. Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis. J Clin Med 2023;12. [PMID: 36769582 DOI: 10.3390/jcm12030934] [Reference Citation Analysis]
|
| 5 |
Ayada I, van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, Lavrijsen M, Janssen HLA, van der Laan LJW, Ghanbari M, Peppelenbosch MP, Zheng MH, de Knegt RJ, Pan Q. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine 2023;87:104392. [PMID: 36502575 DOI: 10.1016/j.ebiom.2022.104392] [Reference Citation Analysis]
|
| 6 |
Su CH, Islam MM, Jia G, Wu CC. Statins and the Risk of Gastric Cancer: A Systematic Review and Meta-Analysis. J Clin Med 2022;11. [PMID: 36498753 DOI: 10.3390/jcm11237180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Tripathi V, Jaiswal P, Sahu K, Majumder SK, Kashyap D, Chandra Jha H, Dixit AK, Parmar HS. Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer. Advances in Cancer Biology - Metastasis 2022;6:100065. [DOI: 10.1016/j.adcanc.2022.100065] [Reference Citation Analysis]
|
| 8 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23:1126-240. [PMID: 36447411 DOI: 10.3348/kjr.2022.0822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Abdallah M, Brown L, Provenza J, Tariq R, Gowda S, Singal AK. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol 2022;27:100738. [PMID: 35781090 DOI: 10.1016/j.aohep.2022.100738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Yip TC, Lai JC, Liang LY, Hui VW, Wong VW, Wong GL. Risk of HCC in Patients with HBV, Role of Antiviral Treatment. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00588-y] [Reference Citation Analysis]
|
| 12 |
Campbell C, Wang T, Gillespie I, Barnes E, Matthews PC. Characterisation of chronic hepatitis B virus infection in the UK and risk factors for hepatocellular carcinoma: a large electronic health record-based retrospective cohort study in the QResearch primary care database.. [DOI: 10.1101/2022.09.01.22279481] [Reference Citation Analysis]
|
| 13 |
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators:. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022;60:1346-421. [PMID: 36100202 DOI: 10.1055/a-1880-2283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 14 |
Wu C, Islam MM, Lee A, Su C, Weng Y, Yeh C, Lee H, Lin M. Association between Statin Use and Risk of Parkinson’s Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals. JPM 2022;12:825. [DOI: 10.3390/jpm12050825] [Reference Citation Analysis]
|
| 15 |
Ong Y, Huey CWT, Shelat VG. Paraneoplastic syndromes in hepatocellular carcinoma: a review. Expert Rev Gastroenterol Hepatol 2022;16:449-71. [PMID: 35649187 DOI: 10.1080/17474124.2022.2085556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Liao X, Ma Q, Wu T, Shao C, Lin Y, Sun Y, Feng S, Wang W, Ye J, Zhong B. Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study. Diabetes Metab Syndr Obes 2022;15:1173-84. [PMID: 35464261 DOI: 10.2147/DMSO.S356371] [Reference Citation Analysis]
|
| 17 |
Sung F, Yeh Y, Muo C, Hsu C, Tsai W, Hsu Y. Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022;14:825. [DOI: 10.3390/cancers14030825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 18 |
Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2022;54:154-63. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 19 |
Azit NA, Sahran S, Voon Meng L, Subramaniam M, Mokhtar S, Mohammed Nawi A. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country. PLoS One 2021;16:e0260675. [PMID: 34882716 DOI: 10.1371/journal.pone.0260675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol 2021;33:1603-9. [PMID: 33405428 DOI: 10.1097/MEG.0000000000002040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. J Hepatol 2021;75:1217-27. [PMID: 34339764 DOI: 10.1016/j.jhep.2021.07.025] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 22 |
Pinyopornpanish K, Al-Yaman W, Butler RS, Carey W, McCullough A, Romero-Marrero C. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021;116:2258-69. [PMID: 34212895 DOI: 10.14309/ajg.0000000000001347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 23 |
Xia B, Peng J, Enrico T, Lu K, Cheung EC, Kuo Z, He Q, Tang Y, Liu A, Fan D, Zhang C, He Y, Pan Y, Yuan J. Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study. BMC Cancer 2021;21:1084. [PMID: 34620113 DOI: 10.1186/s12885-021-08760-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 24 |
Wong YJ, Qiu TY, Ng GK, Zheng Q, Teo EK. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:615-23. [PMID: 33606427 DOI: 10.1097/MCG.0000000000001478] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 25 |
Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res 2021;40:241. [PMID: 34303383 DOI: 10.1186/s13046-021-02041-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 26 |
Bojunga J, Beckerbauer A. Diabetes und Gastroenterologie – Update 2021: Leber, Kolon und Pankreas bei Diabetes mellitus. Diabetologe 2021;17:528-37. [DOI: 10.1007/s11428-021-00780-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 28 |
Zhao L, Deng C, Lin Z, Giovannucci E, Zhang X. Dietary Fats, Serum Cholesterol and Liver Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Studies. Cancers (Basel) 2021;13:1580. [PMID: 33808094 DOI: 10.3390/cancers13071580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 29 |
Alipour Talesh G, Trézéguet V, Merched A. Hepatocellular Carcinoma and Statins. Biochemistry 2020;59:3393-400. [PMID: 32865979 DOI: 10.1021/acs.biochem.0c00476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
